- Home
- NBB vs ALT Comparison
NBB vs ALT Comparison
Compare NBB & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBB | ALT |
|---|---|---|
| Founded | 2009 | 1997 |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.9M | 415.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NBB | ALT |
|---|---|---|
| Price | $16.29 | $4.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 73.9K | ★ 5.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.67 | $2.90 |
| 52 Week High | $16.66 | $7.73 |
Technical Indicators
Market Signals| Indicator | NBB | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 72.92 | 44.92 |
| Support Level | $15.86 | $4.47 |
| Resistance Level | $16.06 | $4.75 |
| Average True Range (ATR) | 0.16 | 0.41 |
| MACD | 0.06 | -0.10 |
| Stochastic Oscillator | 95.59 | 4.50 |
Price Performance
Historical ComparisonAbout NBB Nuveen Taxable Municipal Income Fund of Beneficial Interest
Nuveen Taxable Municipal Income Fund is a closed-end fund incorporated in the United States. Its primary objective is current income through investments in taxable municipal securities; the secondary objective is to seek enhanced portfolio value and total return. The fund invests a majority of its assets in a diversified portfolio of taxable municipal securities.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.